Roche autism drug gets ‘breakthrough’ status from FDA

Jan 29, 2018

A drug being developed by Roche called balovaptan has received a “breakthrough therapy” designation from the FDA. The distinction will put the new treatment on the fast track to approval. 

According to Roche, balovaptan has shown promise at helping those with autism spectrum disorder improve their communication and social interaction skills.

Currently, there is no other medication approved to treat core symptoms of autism. Roche hopes to file for approval of the drugl by 2020.

Read the full Reuters report.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments